Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables - Other (2017 - 2025)

Ultragenyx Pharmaceutical has reported Receivables - Other over the past 9 years, most recently at $1.0 million for Q4 2025.

  • Quarterly Receivables - Other fell 50.0% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 50.0% year-over-year, with the annual reading at $1.0 million for FY2025, 50.0% down from the prior year.
  • Receivables - Other was $1.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $2.1 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $16.0 million in Q4 2021 and troughed at $200000.0 in Q1 2024.
  • The 5-year median for Receivables - Other is $2.4 million (2024), against an average of $3.9 million.
  • Year-over-year, Receivables - Other tumbled 98.43% in 2024 and then surged 1100.0% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $16.0 million in 2021, then plummeted by 60.0% to $6.4 million in 2022, then crashed by 82.81% to $1.1 million in 2023, then soared by 81.82% to $2.0 million in 2024, then crashed by 50.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Receivables - Other are $1.0 million (Q4 2025), $2.1 million (Q3 2025), and $900000.0 (Q2 2025).